Patient satisfaction and duration of effect with PLLA: A review of the literature

Journal of Drugs in Dermatology

Volumn 8, Issue 10, 2009, Pages

  Palm, Melanie D ^a,b   Goldman, Mitchel P ^a  

^a Dermatology & Cosmetic Laser Associates of La Jolla   (United States)

^b Altman Dermatology Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POLYLACTIC ACID; LACTIC ACID; POLYMER;

AGING; ARTICLE; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; ESTHETIC SURGERY; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOATROPHY; PATIENT SATISFACTION; SKINFOLD THICKNESS; TREATMENT DURATION; ADIPOSE TISSUE; ATROPHY; FACE; FEMALE; HIV ASSOCIATED LIPODYSTROPHY; MALE; PATHOLOGY; REVIEW;

ADIPOSE TISSUE; ATROPHY; COSMETIC TECHNIQUES; FACE; FEMALE; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; LACTIC ACID; MALE; PATIENT SATISFACTION; POLYMERS;

EID: 79551533673     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Burgess CM. Poly-L-lactic acid for correction of localized facial lipoatrophy in an otherwise healthy young woman. Dermatol Surg. 2009;35(5):881-884.
2. Hanke CW, Redbord KP. Safety and efficacy of poly-L-lactic acid in HIV lipoatrophy and lipoatrophy of aging. J Drugs Dermatol. 2007;6(2):123-128.
3. Levy RM, Redbord KP, Hanke CW. Treatment of HIV lipoatrophy and lipoatrophy of aging with poly-L-lactic acid: A prospective three-year follow-up study. J Am Acad Dermatol. 2008;59(6):923-933.
4. Lowe NJ, Maxwell CA, Lowe P, Shah A, et al. Injectable poly-L-lactic acid: Three years of aesthetic experience. Dermatol Surg. 2009;35 Suppl 1:344-349.
5. Palm MD, Woodhall KE, Butterwick KJ, Goldman MP. Cosmetic use of poly-L-lactic acid: A retrospective study of 130 patients. Dermatol Surg. 2009 [in press].
6. Redaelli A. Cosmetic use of polylactic acid for hand rejuvenation: Report of 27 patients. J Cosmet Dermatol. 2006;5(3):233-238. (Pubitemid 44314385)
7. Sadick NS. Poly-L-lactic acid: A perspective from my practice. J Cosmet Dermatol. 2008;7(1):55-60. (Pubitemid 351228168)
8. Sadick NS, Palmisano L. Case study involving use of injectable poly-L-lactic acid (PLLA) for acne scars. J Dermatol Treatment. 2009;20:1-6.
9. Salles AG, Lotierzo PH, Gimenez R, Camargo CP, et al. Evaluation of the poly-L-lactic acid implant for treatment of the nasolabial fold: Three-year follow-up evaluation. Aesth Plast Surg. 2008;32(5):753-756.
10. Vleggaar D. Soft-tissue augmentation and the role of poly-L-lactic acid. Plast Reconstr Surg. 2006;118(3 Suppl):46S-54S.
11. Lafaurie M, Dolivo M, Porcher R, Rudant J, et al. Treatment of facial lipoatrophy with intradermal injections of polylactic acid in HIV-infected patients. J Acquir Immune Defic Syndr. 2005;38(3 Suppl):393-398. (Pubitemid 40381548)
12. American Society of Plastic Surgeons. Perception of the Injection. Available at: http://www.plasticsurgery.org/Media/Press-Releases/Perception-of- the-Injection-ASPS-Survey-Reveals-Women-Confused-but-Drawn-to-Facial- Injectables.html. Accessed July 20, 2009.
13. PR newswire. New study reveals what women want when considering cosmetic procedures. Available at: http://www.prnewswire.com/cgi-bin/stories.pl?ACCT= LVRJSVY.story&STORY=/www/story/11-06-2008/0004919755&EDATE= THU+Nov+06+2008,+09:00+AM. Accessed July 20, 2009.
14. Valantin MA, Aubron-Oliver C, Ghosn J, Laglenne E. Polylactic acid implants (New-Fill)® to correct facial lipoatrophy in HIV-infected patients: Results of the open-label study VEGA. AIDS. 2003;17:2471-2477. (Pubitemid 38393319)
15. Burgess CM, Quiroga RM. Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy. J Am Acad Dermatol. 2005;52(2):233-239.
16. Cattelan AM, Bauer U, Trevenzoli M, Sasset L, et al. Use of polylactic acid implants to correct facial lipoatrophy in human immunodeficiency virus 1-positive individuals receiving combination antiretroviral therapy. Arch Dermatol. 2006;142(3):329-334.
17. Moyle GJ, Brown S, Lysakova L, Barton SE. Long-term safety and efficacy of poly-L-lactic acid in the treatment of HIV-related facial lipoatrophy. HIV Med. 2006;7(3):181-185. (Pubitemid 43337597)
18. Piquet M, Brignol L, Chatelain B, Rey D, et al. Polylactic acid injections: usefulness for the treatment of facial lipoatrophy in HIV+ patients under tritherapy. Rev Stomatol Chir Maxillofac. 2007;108:496-504.
19. Mest DR, Humble G. Safety and efficacy of poly-L-lactic acid injections in persons with HIV-associated lipoatrophy: The US experience. Dermatol Surg. 2006;32(11):1336-1345. (Pubitemid 44691136)
20. Mest DR, Humble GM. Retreatment with injectable poly-L-lactic acid for HIV-associated facial lipoatrophy: Twenty-four-month extension of the Blue Pacific study. Dermatol Surg. 2009;35 Suppl 1:350-359.